ReviewCureus2025
Clinical Predictors of Progression From Metabolic Dysfunction-Associated Steatotic Liver Disease to Cirrhosis: A Narrative Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identifying MASLD Patients with MASH or Significant Fibrosis: The Role of Lower ALT Thresholds.Journal of clinical medicine · 2026Article
- From Molecular Mechanisms to Clinical Strategies: A Comprehensive Overview of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) continues to affect many people around the globe and may increase the likelihood of liver-related morbidity and mortality. Early identification of individuals at risk for progression to liver cirrhosis is crucial to the mitigation of the disease effects. This review aims to summarize the current evidence on clinical factors predicting MASLD progression to cirrhosis. A comprehensive literature search was conducted in PubMed, Cochrane, Medscape, JAMA, and Scopus covering studies from May 30, 2010, to May 30, 2025. Keywords included NAFLD, NASH, MASH, cirrhosis, risk factors, fibrosis, and progression. Key predictors identified include metabolic syndrome components (obesity, diabetes, and dyslipidemia), genetic variants such as Patatin-like phospholipase domain-containing protein 3 (PNPLA3), transmembrane 6-superfamily member 2 (TM6SF2), Ras-related protein 14 family (RAB14), lifestyle factors (sedentary behavior, high-fructose diet), demographic traits (age, sex, and ethnicity), and histological markers (fibrosis stage, non-alcoholic steatohepatitis (NASH) features). Non-invasive detection tools such as the Fibrosis-4 (FIB-4) index, non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS), enhanced liver fibrosis (ELF), and perilipin-2 (PLIN2) and elastography are valuable tests for early identification. A combination of metabolic, genetic, lifestyle, and histological factors predicts MASLD progression. Early detection and intervention are critical to prevent cirrhosis. There is a need for more standardized non-invasive tests and their availability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.